Even more impressively, the company says that its batch-tracking analysis indicates that its maximum limits actually tend to be well under-up to 83% under-even its own strict 0.01 mg/kg threshold.
At SupplySide West, Epax AS (Aalesund, Norway) announced that beginning this fall, the company provides customers with a certificate of analysis guaranteeing that all of the firm’s marine omega-3 concentrates meet maximum limits of 0.01 mg/kg for all 209 congeners of polychlorinated biphenyls (PCBs). PCBs are environmental toxins addressed by such regulations as California’s Proposition 65. Epax’s standards for the absence of PCBs are significantly higher than the industry standard.
As Epax explains, current industry PCB standards set a maximum limit of 0.09 mg/kg PCBs, and for only seven PCB congeners. (For instance, this is the maximum limit of the Global Organization for EPA and DHA Omega-3s’ Voluntary Fish Oil Monograph.) By contrast, Epax says, its own omega-3 concentrates meet maximum limits of 0.01 mg/kg-and that is for all 209 congeners, not just seven congeners. Epax says its maximum threshold is nine times lower than current recommended limits, a result of the company’s extremely pure processing and handling process all the way through.
Even more impressively, the company says that its batch-tracking analysis indicates that its maximum limits actually tend to be well under-up to 83% under-even its own strict 0.01 mg/kg threshold. For now, the firm says, it will keep using the 0.01 mg/kg threshold but in the future may lower that maximum limit even further.
The company says that by analyzing concentrates for all 209 PCBs, it will ensure that products do not exceed their safety limits based on recommended dosages. Moreover, it will help marketers meet regulations such as California’s Prop 65. As the company explains:
Current law in the State of California is not based on maximum limits of PCBs as 0.09 mg/kg in total, but on the daily maximum intake per congener. To avoid triggering a Proposition 65 warning requirement in California, consumer products need to make sure that the total exposure of PCBs from the labeled dosage is less than 0.09 mg for all 209 congeners.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.